SG/CALL/ASTRAZENECA/11000/0.1/20.09.24 | Market Closed - Börse Stuttgart 11:45:11 31/05/2024 BST | ||
| 1.68 EUR | +5.00% |
|
| Current month | -1.75% | ||
| 1 month | -1.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 1.68 | +5.00% |
| 30/05/24 | 1.6 | +9.59% |
| 29/05/24 | 1.46 | -19.78% |
| 28/05/24 | 1.82 | +0.55% |
| 27/05/24 | 1.81 | +1.69% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 11:45 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU796U |
| ISIN | DE000SU796U6 |
| Date issued | 13/02/2024 |
| Strike | 11,000 p |
| Maturity | 20/09/2024 (111 Days) |
| Parity | 10 : 1 |
| Emission price | 0.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.03 € |
|---|---|
| Lowest since issue | 0.23 € |
| Spread | 0.11 € |
| Spread % | 5.85% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.90%
- Stock Market
- Warrants
- Warrant
